Brief: Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab
02/02/2026 12:26
Feb 2 (Reuters) - Skye Bioscience Inc SKYE.O: SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RESULTS FOR NIMACIMAB IN COMBINATION WITH SEMAGLUTIDE SKYE BIOSCIENCE INC - 22.3% WEIGHT LOSS AT 52 WEEKS WITH NIMACIMAB + SEMAGLUTIDE (2.4 MG) COMBINATION SKYE BIOSCIENCE INC - FULL TOPLINE REPORTING OF CBEYOND PHASE 2A DATA EXPECTED Q3 2026 Source text: ID:nGNXc9xN7x Further company coverage: SKYE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsRCS - Redx Pharma Limited - Redx to Present Poster on RXC008 at UEG Week
RCS - Redx Pharma Limited - Redx Announces ROCKETEER Phase 2 Trial for RXC008
Brief: Skye Bioscience Says John Sharp Resigns As CFO - SEC Filing
Brief: Skye Bioscience - Enters $22 Million Securities Purchase Agreement With Redmile Biopharma Investments Iii - SEC Filing
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM